<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00453050</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000536471</org_study_id>
    <secondary_id>OU-12576</secondary_id>
    <secondary_id>OU-ISPI</secondary_id>
    <nct_id>NCT00453050</nct_id>
  </id_info>
  <brief_title>Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin</brief_title>
  <official_title>Laser and TLR-Agonist Immunotherapy: A Novel Autologous Melanoma Vaccine Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies, such as imiquimod, may stimulate the immune system in&#xD;
      different ways and stop tumor cells from growing. Laser therapy uses light to kill tumor&#xD;
      cells. Giving imiquimod together with laser therapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects of imiquimod and laser therapy with&#xD;
      or without a green dye in treating patients with stage III or stage IV melanoma that has&#xD;
      spread to other parts of the skin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the toxicity of in situ photoimmunotherapy comprising imiquimod and infrared&#xD;
           laser therapy with or without indocyanine green in patients with stage III or IV&#xD;
           melanoma and cutaneous metastases.&#xD;
&#xD;
        -  Determine the complete systemic and local response rates in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the effect of this treatment on immunologic parameters in these patients.&#xD;
&#xD;
      OUTLINE: This is a prospective, open-label, pilot study.&#xD;
&#xD;
      Patients undergo in situ photoimmunotherapy (ISPI) comprising topical imiquimod twice daily&#xD;
      on days 1-42 and infrared laser therapy (with or without indocyanine green) on days 14 and&#xD;
      28. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Blood is collected at baseline, prior to ISPI, 24 hours after ISPI, and at week 6. Samples&#xD;
      are examined for cytokine response, CD8 T-cell activation and regulatory T-cell assays (by&#xD;
      flow cytometry), and antibody response (by western blot).&#xD;
&#xD;
      After completion of study treatment, patients are followed monthly for 3 months and then&#xD;
      every 3 months for up to 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 70 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity and tolerability by CTCAE version 3.0</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete systemic and local response rates at 16 months</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunologic parameters</measure>
  </secondary_outcome>
  <enrollment type="Actual">11</enrollment>
  <condition>Melanoma (Skin)</condition>
  <condition>Metastatic Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imiquimod</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>indocyanine green solution</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunologic technique</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed melanoma meeting the following criteria:&#xD;
&#xD;
               -  Stage III or IV disease&#xD;
&#xD;
                    -  Stage IV disease without observable, surgically unresectable metastases&#xD;
                       beyond the immediate treatment site allowed&#xD;
&#xD;
               -  Presence of 1 or more cutaneous metastases ≤ 3 cm in size&#xD;
&#xD;
                    -  Diffuse areas of tumor involvement can be used to qualify for the study if&#xD;
                       these areas involve primarily the epidermis and/or dermis and are less than&#xD;
                       3 cm in thickness&#xD;
&#xD;
          -  No uncontrolled brain metastases&#xD;
&#xD;
               -  Treated brain metastases that are stable for 3 months allowed at the&#xD;
                  investigator's discretion&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 4 months&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 1 month after study&#xD;
             completion&#xD;
&#xD;
          -  No known allergy to any drugs used during study treatment&#xD;
&#xD;
          -  No unstable medical illness&#xD;
&#xD;
          -  Not immunosuppressed&#xD;
&#xD;
               -  Patients immunosuppressed due to disease (e.g., HIV positive) allowed&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No systemic steroids or any other immunosuppressive medications within the past month&#xD;
&#xD;
          -  No chemotherapy within the past 4 weeks&#xD;
&#xD;
          -  No radiotherapy to the treatment site within the past 4 weeks&#xD;
&#xD;
               -  Palliative radiotherapy to sites other than cutaneous treatment and assessment&#xD;
                  sites allowed&#xD;
&#xD;
          -  No concurrent immunosuppressive agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Naylor, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Oklahoma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oklahoma University Cancer Institute</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74135-2512</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Li X, Naylor MF, Le H, Nordquist RE, Teague TK, Howard CA, Murray C, Chen WR. Clinical effects of in situ photoimmunotherapy on late-stage melanoma patients: a preliminary study. Cancer Biol Ther. 2010 Dec 1;10(11):1081-7. doi: 10.4161/cbt.10.11.13434. Epub 2010 Dec 1.</citation>
    <PMID>20890121</PMID>
  </reference>
  <reference>
    <citation>Naylor MF, Chen WR, Teague TK, Perry LA, Nordquist RE. In situ photoimmunotherapy: a tumour-directed treatment for melanoma. Br J Dermatol. 2006 Dec;155(6):1287-92.</citation>
    <PMID>17107404</PMID>
  </reference>
  <verification_date>November 2008</verification_date>
  <study_first_submitted>March 27, 2007</study_first_submitted>
  <study_first_submitted_qc>March 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2007</study_first_posted>
  <last_update_submitted>May 5, 2015</last_update_submitted>
  <last_update_submitted_qc>May 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2015</last_update_posted>
  <keyword>stage III melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>skin metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

